©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Dec 18, 2022; 12(12): 394-404
Published online Dec 18, 2022. doi: 10.5500/wjt.v12.i12.394
Published online Dec 18, 2022. doi: 10.5500/wjt.v12.i12.394
Review of heart transplantation from hepatitis C-positive donors
Palak Patel, Department of Cardiology, West Roxbury VA Center, West Roxbury, MA 02132, United States
Nirav Patel, Department of Cardiology, University of Connecticut, Harford Hospital, Hartford, CT 06102, United States
Nirav Patel, Department of Cardiology, University of California, CA 90065, United States
Fahad Ahmed, Department of Internal Medicine, Hartford Hospital, Hartford, CT 06106, United States
Jason Gluck, Advanced Heart Failure, Hartford Hospital, Hartford, CT 06102, United States
Author contributions: Patel P and Patel N contributed to performing the research; Ahmed F contributed to writing the paper; Patel N and Gluck J contributed to designing the research; Patel P, Patel N, and Gluck J contributed to.
Conflict-of-interest statement: All the authors declare having no conflict of interests for this article.
Corresponding author: Jason Gluck, DO, FACC, Attending Doctor, Chief Physician, Advanced Heart Failure, Hartford Hospital, 85 Seymour Street, Hartford, CT 06102, United States. jason.gluck@hhchealth.org
Received: September 9, 2022
Peer-review started: September 9, 2022
First decision: October 21, 2022
Revised: November 3, 2022
Accepted: November 22, 2022
Article in press: November 22, 2022
Published online: December 18, 2022
Processing time: 98 Days and 6.3 Hours
Peer-review started: September 9, 2022
First decision: October 21, 2022
Revised: November 3, 2022
Accepted: November 22, 2022
Article in press: November 22, 2022
Published online: December 18, 2022
Processing time: 98 Days and 6.3 Hours
Core Tip
Core Tip: Given the favorable preliminary data and ongoing opioid epidemic, the utilization of hepatitis C virus-positive hearts is on the rise, which is aiding in the closure of the gap between heart transplantation candidates and donors. Additionally, with future studies evaluating long-term outcomes and standardization of direct-acting antiviral therapy, more transplant centers will accept hepatitis C virus-positive organs.